<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016380</url>
  </required_header>
  <id_info>
    <org_study_id>SC19</org_study_id>
    <secondary_id>CAN-NCIC-SC19</secondary_id>
    <secondary_id>CDR0000068627</secondary_id>
    <nct_id>NCT00016380</nct_id>
  </id_info>
  <brief_title>Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen</brief_title>
  <official_title>A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with
      radiation therapy. It is not yet known if ondansetron is more effective with or without
      dexamethasone in preventing vomiting caused by radiation therapy.

      PURPOSE: This randomized phase III trial is comparing how well ondansetron works with or
      without dexamethasone in preventing vomiting in patients with cancer who are receiving
      radiation therapy to the upper abdomen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the effectiveness of ondansetron with or without dexamethasone as prophylaxis
           for radiation-induced emesis and nausea in patients receiving upper abdominal
           radiotherapy.

        -  Compare toxicity of these regimens in these patients.

        -  Compare quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to radiotherapy field description (whole abdomen and pelvis vs
      partial abdomen and pelvis vs partial abdomen only). Patients are randomized to 1 of 2
      treatment arms.

        -  Arm I: Patients receive oral ondansetron twice daily and oral dexamethasone daily for
           5-7 days concurrently with the first 5 fractions of radiotherapy.

        -  Arm II: Patients receive oral ondansetron twice daily and oral placebo daily for 5-7
           days concurrently with the first 5 fractions of radiotherapy.

      Treatment continues in both arms in the absence of disease progression or unacceptable
      toxicity.

      Quality of life is assessed at baseline, prior to starting radiotherapy if more than 5 days
      since randomization, prior to the 5th and 15th fractions of radiotherapy, and 1 month after
      completion of radiotherapy.

      Patients are followed at 1 month.

      PROJECTED ACCRUAL: A total of 100-200 patients (50-100 per arm) will be accrued for this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Cancer patients who are scheduled to receive radiotherapy within the next 3 weeks

               -  Total dose at least 2,000 cGy delivered in at least 15 fractions

               -  1 fraction per day, 5 days per week

               -  Treatment field to include an area of at least 80 cm2 in the anterior/posterior
                  direction encompassing the upper abdomen

          -  At risk of developing radiation-induced emesis

          -  No emesis (retching and/or vomiting) or nausea with severity greater than 2 within the
             past week

        PATIENT CHARACTERISTICS:

        Age:

          -  16 and over

        Performance status:

          -  ECOG 0-3

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No jaundice

          -  No moderate to severe hepatic dysfunction

        Renal:

          -  Not specified

        Gastrointestinal:

          -  No active peptic ulcer

          -  No lactose intolerance

        Other:

          -  No concurrent condition or illness that contraindicates corticosteroids, serotonin
             antagonists, or prochlorperazine (e.g., diabetes mellitus)

          -  No prior unusual or allergic reaction to a serotonin antagonist (ondansetron,
             dolasetron, or granisetron), corticosteroid, or prochlorperazine

          -  No condition that would preclude accessibility to treatment or follow-up

          -  Able and willing to complete diary and quality of life questionnaires in either
             English or French

          -  Able to swallow

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 1 week since prior cytotoxic therapy

          -  No concurrent cytotoxic therapy

        Endocrine therapy:

          -  No concurrent corticosteroids other than topical or inhaled preparations

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 1 week since prior radiotherapy

          -  No concurrent cranial radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  At least 2 days since prior medication with antiemetic intent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Wong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Valley Cancer Centre at British Columbia Cancer Agency</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Ontario Regional Cancer Care</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS-Hopital Fleurimont</name>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4L 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006 Jul 20;24(21):3458-64.</citation>
    <PMID>16849762</PMID>
  </results_reference>
  <results_reference>
    <citation>Paul N, Wong R, Brundage Michael, et al.: Symptom assessment in SC19: ondansetron plus dexamethasone as prophylaxis against radiation-induced emesis - a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study. [Abstract] Support Care Cancer 13 (6): A-04-033, 419, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Paul N, Wong R, Whitehead M, et al.: Daily diary reporting of symptoms in SC19: a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study of prophylaxis against radiation-induced emesis. [Abstract] Support Care Cancer 13 (6): A-04-034, 419, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Wong R, Paul N, Ding K, et al.: Optimizing prophylaxis of radiation induced emesis (RIE): a phase III double blind randomized study comparing ondansetron plus dexamethasone (OndDex) vs ondansetron alone (OndPlac). [Abstract] Support Care Cancer 13 (6): A-04-043, 423, 2005.</citation>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 25, 2016</last_update_submitted>
  <last_update_submitted_qc>November 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage I gastric cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IA cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>localized gastrointestinal carcinoid tumor</keyword>
  <keyword>regional gastrointestinal carcinoid tumor</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>localized resectable adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>localized gallbladder cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>localized extrahepatic bile duct cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>testicular seminoma</keyword>
  <keyword>carcinoma of the appendix</keyword>
  <keyword>quality of life</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

